Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease

The FDA accepted Belite Bio’s application for tinlarebant to treat Stargardt disease type 1 and set a Feb. 12, 2027, PDUFA decision date. If approved, it would be the first approved treatment for the rare inherited retinal disease. Phase III results showed disease-progression benefits: In the DRAGON trial, once-daily tinlarebant slowed retinal lesion growth by about 35.7% versus placebo, while maintaining an approximately 80% reduction in RBP4 levels. Common eye-related side effects included temporary yellow-tinted vision and delayed dark adaptation; no serious ocular treatment-related events were reported. Belite is preparing for a potential commercial launch: The company is building U.S. sales, physician-education, payer-access and patient-support infrastructure, estimating roughly 53,000 U.S. patients have Stargardt disease type 1, including about 20,000 clinically diagnosed individuals. Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date. At the company’s 2026 Commercial Day, Chairman and CEO Tom Lin said a potential approval would represent a transition for Belite into a commercial-stage biotechnology company. The company is preparing U.S. launch infrastructure, physician education, market-access initiatives and patient-support services while the application remains under FDA review. “If approved, tinlarebant will be the first and only approved treatment for Stargardt disease type 1,” Lin said. No treatment has yet been approved for the progressive inherited retinal disease. Stargardt Disease Burden and Diagnosis Stargardt disease type 1, also called ABCA4-associated retinal dystrophy, is a rare inherited disease that progressively damages central vision while often leaving peripheral vision relatively intact. Michel Michaelides, consultant ophthalmologist at Moorfields Eye Hospital, said the condition is caused by disease-causing variants in the ABCA4 gene, which disrupts removal of vitamin A byproducts from photoreceptors. The resulting accumulation of toxic compounds can lead to retinal pigment epithelium and photoreceptor dysfunction and cell death. Patients speaking during the event described challenges including difficulty reading, recognizing faces, navigating public places, preparing food and traveling independently. They also cited the loss of driving ability and emotional strain associated with progressive vision impairment. Paul Bernstein, an inherited retinal disease specialist at the Moran Eye Center of the University of Utah, said patients are typically referred from optometrists or general ophthalmologists to inherited retinal disease specialists, who conduct imaging and genetic testing to confirm the diagnosis and rule out conditions that can resemble Stargardt disease. Current management largely consists of supportive measures, including low-vision aids, counseling, UV-blocking eyewear and avoiding high-dose vitamin A supplements, Bernstein said. He added that these steps do not alter the disease’s progression. DRAGON Trial Results Michaelides reviewed results from the Phase III DRAGON trial, a randomized, double-masked, placebo-controlled study of once-daily oral tinlarebant in adolescents ages 12 to 20 with Stargardt disease. Participants were assigned tinlarebant 5 milligrams daily or placebo in a 2:1 ratio. The study’s primary endpoint was the annualized growth rate in the area of definitely dec...